Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
CRVS · Why this verdict
Why Corvus Pharmaceuticals (CRVS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.4/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Analyst consensus implies roughly 144% upside from current levels and the stock holds above its 200-day moving average, but the business scores below the minimum quality threshold — burning cash with negative free cash flow and no competitive moat — while 23% of the float is sold short and the put-to-call ratio stands at 55, reflecting deep institutional skepticism about near-term outcomes.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The analyst community prices the stock at a consensus target of $29, implying more than 143% upside from the current share price of $11.90, signaling that if the underlying program succeeds, the market is ascribing substantial probability-weighted value to the pipeline. Sentiment breakdown | Over 12 months, the consensus price target stays above $20.00 and analyst coverage expands beyond its currently light complement as clinical milestones approach. | →Stable |
| CounterAnalyst targets on early-stage biotechs are notoriously optimistic; with a mixed earnings record and no product revenues, the consensus may represent a best-case scenario rather than a risk-adjusted central estimate. | ||
The business scores below the minimum quality threshold, burning cash with negative free cash flow and carrying no competitive moat, meaning the investment case rests entirely on pipeline outcomes rather than any current financial foundation. Quality breakdown | Free cash flow should turn positive — or at minimum cash burn should narrow materially — over the next 12 months for this pillar's concern to be substantially resolved. | →Stable |
| CounterPre-commercial biotechs are expected to burn cash; near-term liquidity appears adequate, and a successful clinical readout could rapidly transform the quality picture. | ||
With 23% of the float sold short, a put-to-call ratio of 55, and implied volatility at 240%, the market is expressing deep skepticism about near-term outcomes — a constellation that typically precedes either a sharp squeeze on positive news or a sharp decline on disappointment. Risk breakdown | A genuine resolution of skepticism would require short interest to fall below 10% and the put-to-call ratio to drop below 5.0 over the next six months. | →Stable |
| CounterExtreme short positioning can itself become a catalyst; any positive clinical data could trigger violent short-covering that temporarily dwarfs the fundamental improvement and drives outsized price appreciation. | ||
Despite quality concerns, the stock trades above its 200-day moving average and a recent RSI pullback to 35 has historically been consistent with a buy opportunity within a continuing uptrend rather than a trend reversal. Momentum breakdown | Over 12 months, price sustains above the 200-day moving average and RSI recovers above 50, confirming the technical uptrend is intact. | →Stable |
| CounterMomentum in speculative names can reverse rapidly; a current RSI pullback may be the beginning of a more significant breakdown if a clinical catalyst disappoints or cash runway concerns surface. | ||
The analyst community prices the stock at a consensus target of $29, implying more than 143% upside from the current share price of $11.90, signaling that if the underlying program succeeds, the market is ascribing substantial probability-weighted value to the pipeline.
→StableSentiment breakdown
- Expectation
- Over 12 months, the consensus price target stays above $20.00 and analyst coverage expands beyond its currently light complement as clinical milestones approach.
CounterAnalyst targets on early-stage biotechs are notoriously optimistic; with a mixed earnings record and no product revenues, the consensus may represent a best-case scenario rather than a risk-adjusted central estimate.
The business scores below the minimum quality threshold, burning cash with negative free cash flow and carrying no competitive moat, meaning the investment case rests entirely on pipeline outcomes rather than any current financial foundation.
→StableQuality breakdown
- Expectation
- Free cash flow should turn positive — or at minimum cash burn should narrow materially — over the next 12 months for this pillar's concern to be substantially resolved.
CounterPre-commercial biotechs are expected to burn cash; near-term liquidity appears adequate, and a successful clinical readout could rapidly transform the quality picture.
With 23% of the float sold short, a put-to-call ratio of 55, and implied volatility at 240%, the market is expressing deep skepticism about near-term outcomes — a constellation that typically precedes either a sharp squeeze on positive news or a sharp decline on disappointment.
→StableRisk breakdown
- Expectation
- A genuine resolution of skepticism would require short interest to fall below 10% and the put-to-call ratio to drop below 5.0 over the next six months.
CounterExtreme short positioning can itself become a catalyst; any positive clinical data could trigger violent short-covering that temporarily dwarfs the fundamental improvement and drives outsized price appreciation.
Despite quality concerns, the stock trades above its 200-day moving average and a recent RSI pullback to 35 has historically been consistent with a buy opportunity within a continuing uptrend rather than a trend reversal.
→StableMomentum breakdown
- Expectation
- Over 12 months, price sustains above the 200-day moving average and RSI recovers above 50, confirming the technical uptrend is intact.
CounterMomentum in speculative names can reverse rapidly; a current RSI pullback may be the beginning of a more significant breakdown if a clinical catalyst disappoints or cash runway concerns surface.
Per-dimension breakdown
Quality
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 70)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.7/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.6 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (6.0) — signal dampened
- ▸Analyst upside: 158%
Insider
6.5/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 6.5 |
| insider conviction | 8.0 |
| holder change | 5.1 |
- ▸Modest insider buying — $333,689 (0.031% of mkt cap)
Peer rank
5.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.2 |
| growth rank | 5.0 |
Technical
1.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.7 |
| support resistance | 0.9 |
| 52w position | 0.0 |
| gap | 6.0 |
Risk (lower is worse)
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.2 |
| days to cover | 0.4 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| beta | 8.0 |
| debt equity | 8.6 |
- ▸High short interest justified: 23%
- ▸Elevated put/call: 2.31
- ▸High IV: 82%
Catalyst
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 1.1 |
| earnings timing | 5.0 |
| surprise avg | 1.8 |
- ▸Earnings concerns: 1B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:6.3>=5.5
- ASYMMETRY:8.3>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:42d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
8.27
Upside
+124.1%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $1.1B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Sentiment at 7.7, and Insider at 6.5; the weakest are Quality at 1.5, Technical at 1.9, and Risk (lower is worse) at 3.1. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 8.27 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The analyst community prices the stock at a consensus target of $29, implying more than 143% upside from the current share price of $11.90, signaling that if the underlying program succeeds, the market is ascribing substantial probability-weighted value to the pipeline.
Trip ifConsensus analyst price target falls below $12.00 (current price), implying no remaining upside.
- P2The business scores below the minimum quality threshold, burning cash with negative free cash flow and carrying no competitive moat, meaning the investment case rests entirely on pipeline outcomes rather than any current financial foundation.
Trip ifFree cash flow rises above $0 for 2 consecutive quarters.
- P3With 23% of the float sold short, a put-to-call ratio of 55, and implied volatility at 240%, the market is expressing deep skepticism about near-term outcomes — a constellation that typically precedes either a sharp squeeze on positive news or a sharp decline on disappointment.
Trip ifShort interest falls below 10% and put-to-call ratio falls below 5.0 for 4 consecutive weeks.
- P4Despite quality concerns, the stock trades above its 200-day moving average and a recent RSI pullback to 35 has historically been consistent with a buy opportunity within a continuing uptrend rather than a trend reversal.
Trip ifPrice closes below the 200-day moving average for 3 consecutive weeks.